药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lumiracoxib
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Vemurafenib.
Lumiracoxib
Olodaterol
The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Vemurafenib.
Lumiracoxib
Histrelin
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Vemurafenib.
Lumiracoxib
Buserelin
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Vemurafenib.
Lumiracoxib
Degarelix
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vemurafenib.
Lumiracoxib
Encorafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Encorafenib.
Lumiracoxib
Dexverapamil
The risk or severity of QTc prolongation can be increased when Dexverapamil is combined with Vemurafenib.
Lumiracoxib
Penfluridol
The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Vemurafenib.
Lumiracoxib
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Vemurafenib.
Lumiracoxib
Lorcainide
The risk or severity of QTc prolongation can be increased when Lorcainide is combined with Vemurafenib.
Lumiracoxib
Bunaftine
The risk or severity of QTc prolongation can be increased when Bunaftine is combined with Vemurafenib.
Lumiracoxib
Nizofenone
The risk or severity of QTc prolongation can be increased when Nizofenone is combined with Vemurafenib.
Lumiracoxib
Otilonium
The risk or severity of QTc prolongation can be increased when Otilonium is combined with Vemurafenib.
Lumiracoxib
Sultopride
The risk or severity of QTc prolongation can be increased when Sultopride is combined with Vemurafenib.
Lumiracoxib
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Vemurafenib.
Lumiracoxib
Oxatomide
The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Vemurafenib.
Lumiracoxib
Abexinostat
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Vemurafenib.
Lumiracoxib
Mizolastine
The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Vemurafenib.
Lumiracoxib
Ricolinostat
The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Vemurafenib.
Lumiracoxib
Simendan
The risk or severity of QTc prolongation can be increased when Simendan is combined with Vemurafenib.